WARRINGTON, Pa., March 22, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
WARRINGTON, Pa., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has completed enrollment in its Phase 2 study of lucinactant (KL4 surfactant) for patients with COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS). Data is anticipated in the first quarter of 2022.
WARRINGTON, Pa., Sept. 29, 2020 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for a Phase 2 clinical trial studying lyo lucinactant, its KL4 surfactant drug, in COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS) patients. Lucinactant is also used in the Company's drug and device combination development program called AEROSURF®, being developed for treating preterm infants with Respiratory Distressed Syndromes.